Galectin Therapeutics Inc.
Galectin Therapeutics is a biopharmaceutical company developing therapies for fibrotic, cancer, and other diseases. Belapectin (GR-MD-02) is its lead product candidate, currently in Phase 2b/3 trials for NASH cirrhosis and liver fibrosis, as well as other indications.
Overview
Strengths
- Skin in the game: insiders own 53% of the shares, aligning management with shareholders.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 6.3% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Shareholder dilution: the share count has grown by 3.1% a year over the last three years.
Key Financial Data